SBIR/STTR Research Award
SBIR Phase I: Development of an oral recombinant subunit vaccine to protect against COVID-19
Award amount
$256,000Program and phase
SBIR · Phase IAward year
2020Award details
- Awarding agency
- National Science Foundation
- Branch
- Not reported
- Recipient company
- VAXFORM LLC
- Proposal award date
- 2020-09-01
- Contract end date
- 2021-08-31
- UEI
- L2PLXD4EA569
- Solicitation number
- Not reported
- Topic code
- PT
Research abstract
The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is to develop a new self-administered vaccine for COVID-19 using a novel oral delivery platform. This project will develop a new technique to genera
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- IND ENABLING STUDIES FOR A GROUP A STREP VACCINE
- SBIR Phase I: Incorporation of a new adjuvant system to produce a thermally stable, orally administered Diphteria-Tetanus-Pertussis vaccine
- Development of a Recombinant Vaccine Against Streptococcus Pyogenes Infection and Disease
- Development of a Recombinant Vaccine Against Streptococcus Pyogenes Infection and Disease
Research funding history
5 SBIR/STTR records share this UEI (2012–2021). Reported award amounts total $1,630,505. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Defense, National Science Foundation, Department of Health and Human Services